Savara, Inc. (SVRA): Price and Financial Metrics
GET POWR RATINGS... FREE!
SVRA POWR Grades
- Sentiment is the dimension where SVRA ranks best; there it ranks ahead of 94.96% of US stocks.
- The strongest trend for SVRA is in Stability, which has been heading up over the past 92 days.
- SVRA's current lowest rank is in the Momentum metric (where it is better than 9.05% of US stocks).
SVRA Stock Summary
- With a price/sales ratio of 138,920, Savara Inc has a higher such ratio than 99.98% of stocks in our set.
- As for revenue growth, note that SVRA's revenue has grown -99.61% over the past 12 months; that beats the revenue growth of just 0.64% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SVRA comes in at -89.77% -- higher than that of only 4.4% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Savara Inc are ARNA, ADCT, FSR, BLU, and NYMX.
- Visit SVRA's SEC page to see the company's official filings. To visit the company's web site, go to www.savarapharma.com.
SVRA Valuation Summary
- SVRA's price/sales ratio is 686.8; this is 5951.1% higher than that of the median Healthcare stock.
- Over the past 53 months, SVRA's price/sales ratio has gone up 355.1.
- SVRA's price/earnings ratio has moved up 5.5 over the prior 53 months.
Below are key valuation metrics over time for SVRA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SVRA | 2021-08-31 | 686.8 | 1.1 | -3.8 | -3.7 |
| SVRA | 2021-08-30 | 629.2 | 1.0 | -3.5 | -3.3 |
| SVRA | 2021-08-27 | 633.5 | 1.0 | -3.5 | -3.4 |
| SVRA | 2021-08-26 | 629.2 | 1.0 | -3.5 | -3.3 |
| SVRA | 2021-08-25 | 598.1 | 0.9 | -3.3 | -3.2 |
| SVRA | 2021-08-24 | 580.2 | 0.9 | -3.2 | -3.1 |
SVRA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SVRA has a Quality Grade of C, ranking ahead of 47.7% of graded US stocks.
- SVRA's asset turnover comes in at 0.002 -- ranking 425th of 682 Pharmaceutical Products stocks.
- SESN, AUPH, and VSTM are the stocks whose asset turnover ratios are most correlated with SVRA.
The table below shows SVRA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.002 | 1 | -0.332 |
| 2021-03-31 | 0.002 | 1 | -0.387 |
| 2020-12-31 | 0.002 | 1 | -0.517 |
| 2020-09-30 | 0.002 | 1 | -0.699 |
| 2020-06-30 | 0.000 | NA | -0.668 |
| 2020-03-31 | 0.000 | NA | -0.723 |
SVRA Price Target
For more insight on analysts targets of SVRA, see our SVRA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.00 | Average Broker Recommendation | 1.42 (Moderate Buy) |
SVRA Stock Price Chart Interactive Chart >
SVRA Price/Volume Stats
| Current price | $1.15 | 52-week high | $3.58 |
| Prev. close | $1.22 | 52-week low | $1.03 |
| Day low | $1.13 | Volume | 356,900 |
| Day high | $1.22 | Avg. volume | 223,750 |
| 50-day MA | $1.19 | Dividend yield | N/A |
| 200-day MA | $1.42 | Market Cap | 130.95M |
Savara, Inc. (SVRA) Company Bio
Savara Inc., a clinical-stage specialty pharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is based in Austin, Texas.
Latest SVRA News From Around the Web
Below are the latest news stories about Savara Inc that investors may wish to consider to help them evaluate SVRA as an investment opportunity.
Savara to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceAUSTIN, Texas, January 04, 2022--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on January 10, 2022 on Savara’s website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days. |
Savara Inc (NASDAQ:SVRA) Director Acquires $28,250.00 in StockSavara Inc (NASDAQ:SVRA) Director David A. Ramsay acquired 25,000 shares of the companys stock in a transaction dated Friday, December 17th. The stock was acquired at an average price of $1.13 per share, for a total transaction of $28,250.00. The purchase was disclosed in a legal filing with the SEC, which is available at the [] |
Brokerages Anticipate Savara Inc (NASDAQ:SVRA) Will Announce Earnings of -$0.07 Per ShareWall Street brokerages forecast that Savara Inc (NASDAQ:SVRA) will report earnings per share of ($0.07) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Savaras earnings. The lowest EPS estimate is ($0.07) and the highest is ($0.06). The business is expected to issue its next quarterly earnings report on Friday, [] |
Savara Inc (NASDAQ:SVRA) Director Acquires $36,400.00 in StockSavara Inc (NASDAQ:SVRA) Director David A. Ramsay bought 35,000 shares of the firm’s stock in a transaction on Friday, December 10th. The stock was bought at an average cost of $1.04 per share, for a total transaction of $36,400.00. The purchase was disclosed in a legal filing with the SEC, which is available through this […] |
Companies - Goldman Sachs Group Inc. Has $236,000 Position in Savara IncGoldman Sachs Group Inc. increased its position in shares of Savara Inc by 44.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities |
SVRA Price Returns
| 1-mo | N/A |
| 3-mo | -4.17% |
| 6-mo | -10.85% |
| 1-year | -35.75% |
| 3-year | -84.52% |
| 5-year | -87.36% |
| YTD | -7.26% |
| 2021 | 7.83% |
| 2020 | -74.33% |
| 2019 | -40.82% |
| 2018 | -48.99% |
| 2017 | 135.56% |
Loading social stream, please wait...